As we have recently shown that loss of the PRC2 gatekeeper Eed promotes inflammation and epithelial-to-mesenchymal transition (EMT) in autochthonous models of Kras-driven NSCLC (Serresi et al., 2016), we next wished to understand whether pharmacological Ezh2 inhibition phenocopies Eed deletion in full. The gene discussed is EZH2; the disease is non-small cell lung carcinoma.